Opendata, web and dolomites

CANDY SIGNED

Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CANDY project word cloud

Explore the words cloud of the CANDY project. It provides you a very rough idea of what is the project "CANDY" about.

sensitive    instance    hyperactivity    translational    transform    somatic    economic    autoimmune    periods    disease    final    id    autism    played    personalized    combination    landscape    hope    co    patient    risk    first    gastrointestinal    academics    immune    synaptic    batteries    tools    disorders    leverage       caused    acting    illnesses    spend    medicine    multidisciplinary    bases    lifespan    guide    converge    team    activation    cancer    treatments    epilepsy    mechanisms    people    population    deficit    underpinning    heterogeneous    intellectual    mental    shows    mortality    clinically    15    stages    neurodevelopmental    asd    imbalance    innovation    ndds    valorization    data    candy    monitoring    strategies    adhd    time    excitation    plasticity    morbidity    neurotransmission    individuals    understand    variants    inhibition    prevention    glutamate    disability    disorder    multimorbidity    gaba    dementia    stratification    lack    hence    world    treatment    genetic    stroke    diagnosis    subgroups    spectrum    smes    shared    biomarkers    life    dysregulation    rare   

Project "CANDY" data sheet

The following table provides information about the project.

Coordinator
STICHTING KATHOLIEKE UNIVERSITEIT 

Organization address
address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ
website: www.radboudumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 6˙000˙000 €
 EC max contribution 6˙000˙000 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) coordinator 1˙615˙000.00
2    KING'S COLLEGE LONDON UK (LONDON) participant 825˙000.00
3    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 500˙000.00
4    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 425˙000.00
5    ARTTIC FR (PARIS) participant 350˙000.00
6    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 350˙000.00
7    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 300˙000.00
8    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 300˙000.00
9    UNIVERSITEIT GENT BE (GENT) participant 300˙000.00
10    RIJKSUNIVERSITEIT GRONINGEN NL (GRONINGEN) participant 250˙000.00
11    UNIVERSITAT BASEL CH (BASEL) participant 250˙000.00
12    NOLDUS INFORMATION TECHNOLOGY BV NL (WAGENINGEN) participant 200˙000.00
13    UNIVERSITAET ULM DE (ULM) participant 150˙000.00
14    BIRKBECK COLLEGE - UNIVERSITY OF LONDON UK (LONDON) participant 125˙000.00
15    ADD INFORMATION SERVICES UK (LONDON) participant 30˙000.00
16    AUTISME-EUROPE AISBL BE (BRUXELLES) participant 30˙000.00

Map

 Project objective

Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), and intellectual disability (ID) are clinically heterogeneous, often co-occur, affect ~15% of the EU population; and are associated with somatic illnesses (e.g. epilepsy, autoimmune and gastrointestinal disease) that lead to a significant increase in morbidity and mortality. For instance in ASD the combination of ID and epilepsy is associated with a reduction in lifespan of ~ 20 years; and an economic cost that is greater than cancer, stroke, or dementia. Yet, the research spend on NDDs is less than 1% of those disorders. Hence, we lack effective new treatments for NDDs and do not understand why they co-occur. There is hope, however. Recent evidence shows that rare genetic variants increasing risk for NDDs are shared, converge on final common pathways (e.g. synaptic plasticity, glutamate and GABA neurotransmission, and excitation/inhibition imbalance), and a key role is likely played by immune dysregulation. CANDY’s innovation is to test, for the first time, if NDDs, and their common mental and somatic multimorbidity, are caused by a combination(s) of common and rare genetic variants and immune activation acting at different ‘sensitive periods’. Our multidisciplinary team of world leading academics, patient organizations and SMEs will cost-effectively leverage existing EU-funded studies to 1) identify novel mechanisms underpinning NDDs and their multimorbidity, 2) develop new strategies for prevention and treatment, 3) deliver novel biomarkers to guide early diagnosis, stratification and/or treatment monitoring, and 4) provide open-access data bases, translational test batteries, and tools and targets for valorization. Together we will transform the landscape for people with NDDs and make possible personalized medicine approaches that target particular mechanisms, in specific subgroups of individuals and at different life stages.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CANDY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CANDY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More  

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More  

ARREST-TB (2019)

Accurate, Rapid, Robust and Economical diagnostic technoliogieS for Tuberculosis

Read More